QBW251

DRUG5 trials

Sponsors

Novartis Pharmaceuticals

Conditions

BronchiectasisChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease, COPDCystic FibrosisPulmonary Disease, Chronic Obstructive

Phase 1

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

TerminatedNCT02190604

Novartis PharmaceuticalsCystic Fibrosis

Start: 2012-07-31End: 2015-11-30Updated: 2020-12-30

Phase 2

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

CompletedNCT02449018

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease, COPD

Start: 2015-04-30End: 2017-01-23Updated: 2021-01-05

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

CompletedNCT04072887

Novartis PharmaceuticalsPulmonary Disease, Chronic Obstructive

Start: 2019-09-12End: 2022-02-01Updated: 2023-04-28

Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

TerminatedNCT04268823

Novartis PharmaceuticalsChronic Obstructive Pulmonary Disease

Start: 2020-09-10End: 2022-09-20Updated: 2024-06-20

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis

TerminatedNCT04396366

Novartis PharmaceuticalsBronchiectasis

Start: 2021-02-02End: 2023-06-21Updated: 2025-09-26

Related Papers

Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.

2023-08-0126 citations

Dose response of icenticaftor in patients with COPD and chronic bronchitis on triple inhaled therapy

05.01 - Airway pharmacology and treatment2022-09-042 citations

Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)

Journal of Cystic Fibrosis2020-12-0623 citations